Tag: global monoclonal antibodies in veterinary health market share

  • Unlocking Opportunities in the Monoclonal Antibodies In Veterinary Health Market: Key Trends, Market Growth, and Forecast Insights

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    What Factors Are Propelling the Market Growth of theMonoclonal Antibodies In Veterinary Health Market from 2025 to 2034?

    The growth of the monoclonal antibodies in the veterinary health market is projected to be propelled by increasing instances of animal diseases. The surge in animal diseases is fueled by heightened farming practices, leading to a higher risk of infectious disease transmission, and alterations in climate, broadening the habitat of disease carriers like ticks and mosquitos. Monoclonal antibodies are beneficial in combatting animal diseases as they aim at specific pathogens or proteins involved in the disease’s manifestation, providing accurate and effective remedies. For example, a report by GOV.UK, a government website based in the UK, revealed that the number of animals culled due to TB attacks increased by 5% in England, reaching 21, 298, and by 17% in Wales, reaching 11,197 between April 2023 and March 2024. These growing instances of animal diseases contribute to the expansion of the monoclonal antibodies in the veterinary health market.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

    How Has the Monoclonal Antibodies In Veterinary Health Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

    The market size of monoclonal antibodies in veterinary health has seen a swift expansion in recent times. It is projected to expand from $0.8 billion in 2024 to $0.92 billion in 2025, boasting a compound annual growth rate (CAGR) of 15.2%. Factors like the surge in worldwide pet ownership, rising instances of chronic diseases in animals, growing pet adoption rates, and heightened health awareness among pet owners contributed to the growth recorded in the historic period.

    Expectations for the monoclonal antibodies in the veterinary health market size suggest swift expansion in the upcoming years. By 2029, it is projected to have risen to $1.61 billion, with a compound annual growth rate (CAGR) of 15.0%. The anticipated growth in the forecasted period is tied to factors such as an escalating pet population, increased spending on pets, intensified occurrences of canine atopic dermatitis, surging demand for superior veterinary healthcare, and heightened awareness of animal health. The forecasted period also anticipates key trends including breakthroughs in biotechnological research, genetic engineering enhancements, inventive treatments, advancements in therapeutic antibodies, and technological progress in antibody engineering.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20575

    How Are Market Trends and Innovations Revolutionizing theMonoclonal Antibodies In Veterinary Health Industry in Recent Times?

    Leading corporations within the monoclonal antibodies in veterinary health market are directing their efforts to create inventive veterinary therapeutic options, like anti-NGF monoclonal antibody therapies, which aim to alleviate chronic pain and inflammation in animals. The anti-NGF therapy works by targeting and suppressing nerve growth factor (NGF) which in turn, reduces pain and inflammation in animals with chronic pain. For example, Zoetis, a US-based animal health firm, secured FDA approval in May 2023 for Librela (bedinvetmab injection), marking it as the first monoclonal antibody therapy designed for pain management in osteoarthritic dogs. It is provided through a monthly injection. Additionally, they introduced Apoquel Chewable, the first chewable drug designed specifically for controlling allergic itch and inflammation in dogs aged over a year. Librela is an antibody that restricts and suppresses NGF and by blocking NGF, it inhibits pain signals from reaching the brain thus, reducing pain in canines suffering from osteoarthritis. It signifies a key progression in veterinary pain management, offering a novel method for addressing chronic pain in canines.

    Which Key Market Players Are Shaping the Future and Growth of theMonoclonal Antibodies In Veterinary Health Market?

    Major companies operating in the monoclonal antibodies in veterinary health market are Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Zoetis Inc., MSD Animal Health, Elanco Animal Health Incorporated, Bio-Rad Laboratories Inc., Eli Lilly and Company, GenScript Biotech Corporation, Abcam plc, Heska Corporation, Neogen Corporation, iNova Pharmaceuticals, Ceva Santé Animale S.A., Biogénesis Bagó S.A., TransGen Biotech Co. Ltd., AbCellera Biologics Inc., Areteia Therapeutics Inc., Esco Aster Pte Ltd, PetMedix Ltd., Vaxine Pty Ltd

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report

    What Are the Core Segments of the Monoclonal Antibodies In Veterinary Health Market, and How Do They Contribute to Growth?

    The monoclonal antibodies in veterinary health market covered in this report is segmented –

    1) By Animal Type: Dogs, Other Animal Types

    2) By Application: Dermatology, Pain, Other Applications

    3) By End-User: Veterinary Hospitals, Other End-Users

    Subsegments:

    1) By Dogs: Canine Infectious Diseases, Canine Cancer Treatment, Canine Autoimmune Disorders, Canine Allergies

    2) By Other Animal Types: Cats, Horses, Cattle, Swine, Poultry, Aquatic Animals, Small Mammals

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=20575&type=smp

    What Regions Are Dominating the Monoclonal Antibodies In Veterinary Health Market Growth?

    North America was the largest region in the monoclonal antibodies in veterinary health market in 2024. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Monoclonal Antibodies In Veterinary Health Market 2025, By The Business Research Company:

    Veterinary Pain Management Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/veterinary-pain-management-global-market-report

    Veterinary Reference Laboratory Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/veterinary-reference-laboratory-global-market-report

    Veterinary Radiosurgery System Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/veterinary-stereotactic-radiosurgery-system-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Comprehensive Analysis of the Monoclonal Antibodies In Veterinary Health Market 2025-2034: Growth Rates, Trends, and Future Opportunities

    Comprehensive Analysis of the Monoclonal Antibodies In Veterinary Health Market 2025-2034: Growth Rates, Trends, and Future Opportunities

    Get 20% OFF on all 2025 Global Market Reports until March 31st! Apply code FY25SAVE and grab your savings today!

    How has the monoclonal antibodies in veterinary health market grown over the years?

    The size of the monoclonal antibodies market in veterinary health has seen a rapid expansion in the past few years. The market, which was worth $0.8 billion in 2024, is expected to grow to $0.92 billion in 2025, with a compound annual growth rate (CAGR) of 15.2%. The spectacular growth throughout the historic period can be linked to several factors including the rise in pet ownership across the globe, a surge in chronic disease cases among animals, an uptick in pet adoption rates, and growing health awareness among pet owners.

    What Is the forecasted market size and growth rate for the monoclonal antibodies in veterinary health market?

    The market size of monoclonal antibodies in veterinary health is predicted to experience a quick expansion in the upcoming years, reaching $1.61 billion in 2029 with a compound annual growth rate (CAGR) of 15.0%. This projected growth across the forecast period can be credited to a rise in pet populations, an increase in expenditure on pets, a growing rate of canine atopic dermatitis, an amplified demand for sophisticated veterinary healthcare, and an escalating focus on animal health. Key trends anticipated during the forecast period include developments in biotechnology and research, progressions in genetic engineering, innovative therapies, advancements in therapy based on antibodies, and technological progress in antibody engineering.

    Get your monoclonal antibodies in veterinary health market report here!

    https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report

    What are the major factors driving growth in the monoclonal antibodies in veterinary health market?

    The growth of the monoclonal antibodies in the veterinary health market is likely to be fueled by increasing incidents of animal diseases. These rise in diseases can be attributed to intensified farming methods that amplify the risk of infectious diseases and global climate changes that broaden the disease carriers such as ticks and mosquitoes. Monoclonal antibodies play a crucial role in curing animal diseases as they specially target the pathogens or proteins that play a role in disease development, providing precise and efficient remedies. For example, a GOV.UK report published in June 2024 indicated a 5% increase in animals being put down due to TB incidents in England, with a total of 21,298, and a 17% increase in Wales, with a total of 11,197, between April 2023 and March 2024. This surge in animal diseases is stimulating the expansion of the monoclonal antibodies in the veterinary health market.

    What key areas define the segmentation of the global monoclonal antibodies in veterinary health Market?

    The monoclonal antibodies in veterinary health market covered in this report is segmented –

    1) By Animal Type: Dogs, Other Animal Types

    2) By Application: Dermatology, Pain, Other Applications

    3) By End-User: Veterinary Hospitals, Other End-Users

    Subsegments:

    1) By Dogs: Canine Infectious Diseases, Canine Cancer Treatment, Canine Autoimmune Disorders, Canine Allergies

    2) By Other Animal Types: Cats, Horses, Cattle, Swine, Poultry, Aquatic Animals, Small Mammals

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

    What are the top market players propelling the growth of the monoclonal antibodies in veterinary health industry?

    Major companies operating in the monoclonal antibodies in veterinary health market are Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Zoetis Inc., MSD Animal Health, Elanco Animal Health Incorporated, Bio-Rad Laboratories Inc., Eli Lilly and Company, GenScript Biotech Corporation, Abcam plc, Heska Corporation, Neogen Corporation, iNova Pharmaceuticals, Ceva Santé Animale S.A., Biogénesis Bagó S.A., TransGen Biotech Co. Ltd., AbCellera Biologics Inc., Areteia Therapeutics Inc., Esco Aster Pte Ltd, PetMedix Ltd., Vaxine Pty Ltd

    What are the key trends shaping the future of the monoclonal antibodies in veterinary health market?

    Leading corporations within the monoclonal antibodies in veterinary health market are steering towards the creation of novel therapeutic solutions in veterinary health, among them being the anti-NGF monoclonal antibody treatment, specifically designed to alleviate chronic pain and inflammation in animals. This therapeutic process works by focusing on and limiting nerve growth factor (NGF) in order to diminish the suffering of animals from chronic pain. An example of this was noted in May 2023 when Zoetis, a US animal health company, was given FDA clearance for Librela (bedinvetmab injection) – the first of its kind monoclonal antibody treatment which moderates pain related to osteoarthritis (OA) in dogs, applied through a monthly injection, and Apoquel Chewable, a unique chewable medication tailored to manage allergic itch and inflammation in dogs a year old and above. Librela is a monoclonal antibody that works to target and suppress nerve growth factor (NGF), preventing the brain from receiving pain signals and thereby lessening the pain felt by dogs with osteoarthritis. The introduction of Librela symbolises a significant progress in the field of veterinary pain management by offering a creative solution to chronic pain in dogs.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20575

    What regions are dominating the monoclonal antibodies in veterinary health market growth?

    North America was the largest region in the monoclonal antibodies in veterinary health market in 2024. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Similar Reports By The Business Research Company:

    Veterinary Pain Management Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/veterinary-pain-management-global-market-report

    Veterinary Reference Laboratory Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/veterinary-reference-laboratory-global-market-report

    Veterinary Radiosurgery System Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/veterinary-stereotactic-radiosurgery-system-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • In-Depth Insights into the Monoclonal Antibodies In Veterinary Health Market: Growth, Trends, and Opportunities for 2025-2034

    In-Depth Insights into the Monoclonal Antibodies In Veterinary Health Market: Growth, Trends, and Opportunities for 2025-2034

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    What Future CAGR is Anticipated for the Monoclonal Antibodies In Veterinary Health Market Over the 2025–2034 Period?

    The market size for monoclonal antibodies in veterinary health has observed significant expansion in the recent past. It is predicted to escalate from $0.8 billion in 2024 to $0.92 billion in 2025 with an impressive compound annual growth rate (CAGR) of 15.2%. Factors contributing to this growth during the historical period include the global surge in pet ownership, the increase in chronic diseases among animals, the rise in pet adoption rates and heightened health awareness amongst pet owners.

    Expectations are high for a swift expansion in the monoclonal antibodies in veterinary health market in the coming years. The market is predicted to reach $1.61 billion by 2029 with a compound annual growth rate (CAGR) of 15.0%. Factors contributing to this expected growth during the forecast period include an increased pet population, higher spending on pets, a surge in canine atopic dermatitis, a rising demand for more advanced veterinary healthcare, and an increased focus on animal health. The trends to look out for during the forecast period comprise advancements in biotechnology and research, progression in genetic engineering, pioneering treatments, advancements in therapies based on antibodies, and technological advancements in antibody engineering.

    How Are the key drivers expanding the growth of the Monoclonal Antibodies In Veterinary Health Market?

    The growth of the monoclonal antibodies in veterinary health market is anticipated to be driven by an increase in animal disease incidences. Intensified farming practices and climate change, which enhances the spread of disease vectors like ticks and mosquitoes, are causing a surge in animal diseases. Monoclonal antibodies offer precise and effective treatments as they focus on particular pathogens or proteins linked to disease processes, which makes them incredibly beneficial for treating animal diseases. For example, a report by the GOV.UK, a government website based in the UK, recorded in June 2024 that from April 2023 to March 2024, the amount of animals scrapped due to TB incidents escalated by 5% in England to 21,298, and by 17% in Wales to 11,197. These increasing animal disease incidences are propelling the growth of the monoclonal antibodies in veterinary health market.

    Get Your Free Sample of the Global Monoclonal Antibodies In Veterinary Health Market Report Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp

    Who Are the Influential Players Fueling Innovation and Growth in the Monoclonal Antibodies In Veterinary Health Market?

    Major companies operating in the monoclonal antibodies in veterinary health market are:

    • Sanofi S.A.

    • Bristol-Myers Squibb Company

    • GlaxoSmithKline plc (GSK)

    • Amgen Inc.

    • Boehringer Ingelheim International GmbH

    What Impact Are Industry Trends Having on the Monoclonal Antibodies In Veterinary Health Market’s Future Prospects?

    Key players in the monoclonal antibodies in veterinary health market are prioritizing the creation of novel veterinary therapeutic solutions, like anti-NGF monoclonal antibody therapy, to handle chronic pain and inflammation in animals. This specific treatment is aimed at targeting and interrupting nerve growth factor (NGF) to alleviate pain and inflammation in animals dealing with enduring painful conditions. Take for example Zoetis, a U.S-based animal health company, which won FDA approvals in May 2023 for their products; Librela (bedinvetmab injection) and Apoquel Chewable. Librela, the first-of-its-kind monoclonal antibody therapy for managing pain related to osteoarthritis (OA) in dogs, is given through a monthly injection; while Apoquel Chewable is the first chewable drug specifically designed to control allergic itching and inflammation in dogs aged one year and above. Librela works by targeting and blocking NGF, thus preventing pain signals from reaching the brain and consequently reducing the dog’s pain perception. This represents a notable progression in veterinary pain management, introducing an innovative way of managing chronic pain in dogs.

    Secure Your Global Monoclonal Antibodies In Veterinary Health Market Report Now for Fast and Efficient Delivery!

    https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report

    How Are the Key Segments of the Monoclonal Antibodies In Veterinary Health Market Impacting Its Expansion and Revenue Streams?

    The monoclonal antibodies in veterinary health market covered in this report is segmented –

    1) By Animal Type: Dogs, Other Animal Types

    2) By Application: Dermatology, Pain, Other Applications

    3) By End-User: Veterinary Hospitals, Other End-Users

    Subsegments:

    1) By Dogs: Canine Infectious Diseases, Canine Cancer Treatment, Canine Autoimmune Disorders, Canine Allergies

    2) By Other Animal Types: Cats, Horses, Cattle, Swine, Poultry, Aquatic Animals, Small Mammals

    What Regions Are Leading the Growth Trajectory of the Monoclonal Antibodies In Veterinary Health Market?

    North America was the largest region in the monoclonal antibodies in veterinary health market in 2024. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    How Do Experts Define the Scope of the Monoclonal Antibodies In Veterinary Health Market?

    Monoclonal antibodies in veterinary health are specialized proteins engineered to target and neutralize specific pathogens or toxins in animals, aiding in the diagnosis and treatment of various diseases. They are created by cloning a single type of immune cell to produce identical antibodies that precisely bind to their target.

    Browse Through More Similar Reports By The Business Research Company:

    Veterinary Pain Management Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/veterinary-pain-management-global-market-report

    Veterinary Reference Laboratory Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/veterinary-reference-laboratory-global-market-report

    Veterinary Radiosurgery System Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/veterinary-stereotactic-radiosurgery-system-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: